PT-150 is under clinical development by Palisades Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PT-150’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 30 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 30 Dec 2021 increased PT-150’s Phase Transition Success Rate (PTSR) for Ovarian Cancer, and increased PTSR for Pancreatic Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PT-150 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PT-150 is under development for the treatment of opiod nicotine addiction, alcohol addiction, pancreatic cancer, glioblastoma, treatment-resistant prostate cancer, ovarian cancer, TNBC and Covid-19. It acts by targeting GR translocation and corticosterone-induced GR translocation. It was also under development for the treatment of psychotic major depression, breast cancer and ovarian cancer. The drug candidate in combination with chemo therapeutics used as a chemo sensetizer.
Quick View PT-150 LOA Data
|Highest Development Stage|